問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital (在職)

Division of Urology

Division of Infectious Disease

Division of Urology

更新時間：2023-09-19

吳建志WU, CHIEN-CHIH
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 7 years 10 個月

Recruiting Trial

10Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳建志

List

10Cases

2025-09-01 - 2029-12-31

Not yet recruiting
A Phase 2, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540A in Healthy Females 16 to 26 Years of Age

  • Condition/Disease

    Healthy

  • Test Drug

    Injectables

Participate Sites
6Sites

Recruiting6Sites

2017-01-01 - 2017-12-31

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2024-11-01 - 2025-11-15

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2024-10-01 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-09-01 - 2026-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2023-09-01 - 2027-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-12-01 - 2026-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2019-07-01 - 2022-09-30

Phase I

A single-blinded, randomized, placebo-controlled, dose escalation, Phase 1 study to investigate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of UB-852 after a single subcutaneous administration in healthy male adults

  • Condition/Disease

    Anemia in chronic kidney disease

  • Test Drug

    UB-852

Participate Sites
1Sites

Recruiting1Sites

2020-09-25 - 2022-11-17

Phase I/II

A Phase I/IIa Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of AR100DP1 in Healthy Subjects, and Subjects with Mild to Moderate Atopic Dermatitis

  • Condition/Disease

    Atopic Dermatitis (AD)

  • Test Drug

    AR100DP1

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2016-02-01 - 2017-01-31

Phase I

A randomized, double-blind, placebo-controlled, single ascending dose first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CFZ533 in healthy subjects and rheumatoid arthritis patients

  • Condition/Disease

    Rheumatoid arthritis

  • Test Drug

    CFZ533

Participate Sites
1Sites

Terminated1Sites

劉明哲
Taipei Medical University Hospital

Division of Urology

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB